


# Psoriatic Arthritis

## LSCMMG Recommended Treatment Pathway

Therapy should always be initiated with the most cost effective drug, based on clinical judgement for the individual patient.



Biologic	TA	Additional or alternative conditions for use			Response	
					Assess response after	Definition of adequate response
Adalimumab	199				12 weeks	<p>An improvement in at least two of the four PsARC criteria, (one of which has to be joint tenderness or swelling score) with no worsening in any of the four criteria.</p> <p>People whose disease has a Psoriasis Area and Severity Index (PASI) 75 response at 12 weeks but whose PsARC response does not justify continuation of treatment should be assessed by a dermatologist to determine whether continuing treatment is appropriate on the basis of skin response.</p>
Etanercept						
Infliximab						
Certolizumab Pegol	445	<p><b>OR</b> The person has had a TNF-alpha inhibitor but their disease has <b>stopped</b> responding after the first 12 weeks.</p>			12 weeks	
Secukinumab**			<p><b>OR</b> The person has had a TNF-alpha inhibitor but their disease has <b>not</b> responded within the first 12 weeks.</p>	<p><b>OR</b> TNF-alpha inhibitors are contraindicated but would otherwise be considered.</p>	16 weeks	
Ixekizumab**	537				16 weeks	
Tofacitinib**	543		12 weeks			
Golimumab	220				16 weeks	
Apremilast	433				24 weeks	
Ustekinumab*	340	<p><b>AND</b> TNF-alpha inhibitors are contraindicated but would otherwise be considered.</p>	<p><b>OR</b> The person has had treatment with 1 or more TNF-alpha inhibitors.</p>			
Guselkumab*	815					12 weeks
Upadacitinib*	768					16 weeks
Risankizumab	803	<p><b>AND</b> Has moderate to severe psoriasis.</p>	<p><b>AND</b> Has had at least 1 biological DMARD.</p>			16 weeks